J
John G.F. Cleland
Researcher at National Institutes of Health
Publications - 1276
Citations - 125527
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 137, co-authored 1172 publications receiving 110227 citations. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Papers
More filters
Journal ArticleDOI
Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: darbepoetin alfa study, ECHOS, and ASCOT-BPLA.
TL;DR: Preliminary results of the ASCOT‐BPLA study showed that in hypertensive patients, treatment with a calcium antagonist plus an ACE inhibitor was more effective at reducing cardiovascular outcomes than atenolol plus a diuretic.
Journal ArticleDOI
Development and course of heart failure after a myocardial infarction in younger and older people.
TL;DR: The risk of developing HF and of dying after an MI increases progressively with age, Regardless of age, most deaths after a MI are preceded by the development of HF.
Journal ArticleDOI
Heart 'omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database.
Lotte Jacobs,Lutgarde Thijs,Yu Jin,Faiez Zannad,Alexandre Mebazaa,Philippe Rouet,Florence Pinet,Christophe Bauters,Burkert Pieske,Andreas Tomaschitz,Mamas A. Mamas,Javier Díez,Kenneth McDonald,John G.F. Cleland,Hans-Peter Brunner-La Rocca,Stephane Heymans,Roberto Latini,Serge Masson,Peter S. Sever,Christian Delles,Stuart J. Pocock,Timothy Collier,Tatiana Kuznetsova,Jan A. Staessen +23 more
TL;DR: A large clinical database, based on prospective population studies or cross-sectional, prospective studies or randomized controlled trials of patients at risk for or with overt cardiovascular disease will be constructed to determine most promising ‘omics’-based biomarkers to identify the risk of developing heart failure and/or comorbidities.
Journal ArticleDOI
Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission
Paloma Pandhi,Jozine M. ter Maaten,Johanna E. Emmens,Joachim Struck,Andreas Bergmann,John G.F. Cleland,Michael M. Givertz,Marco Metra,Christopher M. O'Connor,John R. Teerlink,Piotr Ponikowski,Gad Cotter,Beth A. Davison,Dirk J. van Veldhuisen,Adriaan A. Voors +14 more
TL;DR: Whether bio‐ADM levels at discharge from a hospital admission for worsening HF could provide additional information on (residual) congestion status, diuretic dose titration and clinical outcomes is studied.
Journal ArticleDOI
The electrocardiogram is a more sensitive indicator than echocardiography of hypertrophic cardiomyopathy in families with a mutation in the MYH7 gene.
Sahar Al-Mahdawi,Susan Chamberlain,Lidia Chojnowska,E Michalak,Petros Nihoyannopoulos,M Ryan,B Kusnierczyk,Julie French,DavidM Gilligan,John G.F. Cleland +9 more
TL;DR: Identification of a specific mutation gives no guide to the clinical phenotype, and there is considerable variability in the phenotypic expression of hypertrophic cardiomyopathy.